There is little that resembles a current and all-encompassing drug policy in the United States. A national drug control plan issued by the Obama administration last year was written immediately prior to a White House transition, and many hoping for a newer framework are waiting for next month’s reveal of a new presidential commission’s final report on the opioid epidemic.  

A new analysis by the Kaiser Family Foundation, however, shows that many of the elements that could soon be codified as federal guidance are already creeping toward national standards in a patchwork fashion, apparent in the regulations imposed by a number of states for implementing Medicaid.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy